Try our mobile app
Exhibit 99.1
| CONTACT | |||
| DR. REDDY'S LABORATORIES LTD. | Investor relationS | Media relationS | |
| 8-2-337, Road No. 3, Banjara Hills, | AMIT AGARWAL | USHA iyer | |
| Hyderabad - 500034. Telangana, India. | amita@drreddys.com | ushaiyer@drreddys.com | |
Dr. Reddy’s Q1 FY22 Financial Results
Hyderabad, India, July 27, 2021: Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter ended June 30, 2021. The information mentioned in this release is on the basis of consolidated financial statements under International Financial Reporting Standards (IFRS).
| Revenues | Rs. 4,919 Cr |
| [Up: 11% YoY; Up: 4% QoQ] | |
| Gross Margin | 52.2% |
| [Q1 FY21: 56.0%; Q4 FY21: 53.7%] | |
| SG&A Expenses | Rs. 1,505 Cr |
| [Up: 18% YoY; Up: 5% QoQ] | |
| R&D Expenses | Rs. 453 Cr |
| [9.2% of Revenues] | |
| EBITDA | Rs. 1,019 Cr |
| [20.7% of Revenues] | |
| Profit before Tax* | Rs. 743 Cr |
| [Down: 16% YoY; Up: 21% QoQ] | |
| Profit after Tax* | Rs. 571 Cr |
| [Down: 1% YoY; Up: 58% QoQ] |
* Q4 FY21 financials have been adjusted with an additional charge of Rs. 191 Cr ($ 26.25 mn) arising out of the arbitration award in favor of Hatchtech towards the Xeglyze product as an adjusting subsequent event for filing IFRS financials with US SEC in Form 20F on June 30, 2021.
Commenting on the results, Co-Chairman & MD, G V Prasad said “The financial performance of the quarter has been driven by healthy sales growth. I am confident about improving our margins in the upcoming quarters which will be led by the scale up of recent launches, new product launches and productivity. While we continue to sharpen execution in our core business, we are also conducting pilots in areas such as Nutrition, Direct-to-Customer, and Digital Health & Wellness, which can be future growth drivers”.
| 1 |
| All amounts in millions, except EPS | All US dollar amounts based on convenience translation rate of I USD = Rs. 74.33 |
Dr. Reddy’s Laboratories Limited and Subsidiaries
Consolidated Income Statement
| Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ | ||||||||||||||||||||||||||||
| Particulars | ($) | (Rs.) | ($) | (Rs.) | Gr % | ($) | (Rs.) | Gr% | ||||||||||||||||||||||||
| Revenues | 662 | 49,194 | 594 | 44,175 | 11 | 636 | 47,284 | 4 | ||||||||||||||||||||||||
| Cost of Revenues | 316 | 23,495 | 261 | 19,420 | 21 | 295 | 21,909 | 7 | ||||||||||||||||||||||||
| Gross Profit | 346 | 25,699 | 333 | 24,755 | 4 | 341 | 25,375 | 1 | ||||||||||||||||||||||||
| Operating Expenses | ||||||||||||||||||||||||||||||||
| Selling, General & Administrative expenses | 202 | 15,045 | 172 | 12,786 | 18 | 193 | 14,370 | 5 | ||||||||||||||||||||||||
| Research and Development expenses | 61 | 4,534 | 54 | 3,980 | 14 | 55 | 4,094 | 11 | ||||||||||||||||||||||||
| Impairment of non-current assets | - | - | - | - | - | 25 | 1,835 | (100 | ) | |||||||||||||||||||||||
| Other operating income | (7 | ) | (487 | ) | (2 | ) | (118 | ) | 313 | (8 | ) | (587 | ) | (17 | ) | |||||||||||||||||
| Results from operating activities | 89 | 6,607 | 109 | 8,107 | (19 | ) | 76 | 5,663 | 17 | |||||||||||||||||||||||
| Net finance income | (9 | ) | (652 | ) | (8 | ) | (605 | ) | 8 | (4 | ) | (318 | ) | 105 | ||||||||||||||||||
| Share of profit of equity accounted investees | (2 | ) | (166 | ) | (1 | ) | (77 | ) | 116 | (2 | ) | (179 | ) | (7 | ) | |||||||||||||||||
| Profit before income tax | 100 | 7,425 | 118 | 8,789 | (16 | ) | 83 | 6,160 | 21 | |||||||||||||||||||||||
| Income tax (benefit) / expense | 23 | 1,717 | 40 | 2996 | (43 | ) | 34 | 2,536 | (32 | ) | ||||||||||||||||||||||
| Profit for the period | 77 | 5,708 | 78 | 5,793 | (1 | ) | 49 | 3,624 | 58 | |||||||||||||||||||||||
| Diluted Earnings Per Share (EPS) | 0.46 | 34.34 | 0.47 | 34.86 | (1 | ) | 0.29 | 21.80 | 58 | |||||||||||||||||||||||
| As % to revenues | Q1 FY22 | Q1 FY21 | Q4 FY21 | |||||||||
| Gross Profit | 52.2 | 56.0 | 53.7 | |||||||||
| SG&A | 30.6 | 28.9 | 30.4 | |||||||||
| R&D | 9.2 | 9.0 | 8.7 | |||||||||
| EBITDA | 20.7 | 26.3 | 23.8 | |||||||||
| PBT | 15.1 | 19.9 | 13.0 | |||||||||
| PAT | 11.6 | 13.1 | 7.7 | |||||||||
EBITDA Computation
| Q1 FY22 | Q1 FY21 | Q4 FY21 | ||||||||||||||||||||||
| Particulars | ($) | (Rs.) | ($) | (Rs.) | ($) | (Rs.) | ||||||||||||||||||
| Profit before Income Tax | 100 | 7,425 | 118 | 8,789 | 83 | 6,160 | ||||||||||||||||||
| Interest (income) / expense (net)* | (2 | ) | (142 | ) | (4 | ) | (306 | ) | 1 | 75 | ||||||||||||||
| Depreciation | 27 | 1,973 | 29 | 2,120 | 28 | 2,089 | ||||||||||||||||||
| Amortization | 13 | 932 | 14 | 1,020 | 15 | 1,080 | ||||||||||||||||||
| Impairment | - | - | - | - | 25 | 1,835 | ||||||||||||||||||
| EBITDA | 137 | 10,188 | 156 | 11,622 | 151 | 11,239 | ||||||||||||||||||
| * | Includes income from Investments |
| 2 |
| All amounts in millions, except EPS | All US dollar amounts based on convenience translation rate of I USD = Rs. 74.33 |
Key Balance Sheet Items
| As
on 30th Jun 2021 | As
on 31st Mar 2021 | As
on 30th Jun 2020 | ||||||||||||||||||||||
| Particulars | ($) | (Rs.) | ($) | (Rs.) | ($) | (Rs.) | ||||||||||||||||||
| Cash and cash equivalents and other investments | 462 | 34,356 | 532 | 39,531 | 380 | 28,227 | ||||||||||||||||||
| Trade receivables (current & non-current) | 823 | 61,148 | 669 | 49,759 | 650 | 48,316 | ||||||||||||||||||
| Inventories | 683 | 50,771 | 611 | 45,412 | 527 | 39,148 | ||||||||||||||||||
| Property, plant and equipment | 789 | 58,636 | 768 | 57,111 | 729 | 54,183 | ||||||||||||||||||
| Goodwill and Other Intangible assets | 535 | 39,746 | 541 | 40,216 | 619 | 45,991 | ||||||||||||||||||
| Loans and borrowings (current & non-current) | 449 | 33,373 | 408 | 30,308 | 425 | 31,582 | ||||||||||||||||||
| Trade payables | 385 | 28,607 | 319 | 23,744 | 256 | 19,038 | ||||||||||||||||||
| Equity | 2,396 | 1,78,114 | 2,328 | 1,73,062 | 2,176 | 1,61,748 | ||||||||||||||||||
Revenue Mix by Segment
| Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ | ||||||||||||||||
| Segment | (Rs.) | (Rs.) | Gr % | (Rs.) | Gr % | |||||||||||||||
| Global Generics | 41,113 | 35,075 | 17 | 38,737 | 6 | |||||||||||||||
| North America | 17,390 | 17,282 | 1 | 17,491 | (1 | ) | ||||||||||||||
| Europe | 3,994 | 3,551 | 12 | 3,956 | 1 | |||||||||||||||
| India | 10,600 | 6,260 | 69 | 8,445 | 26 | |||||||||||||||
| Emerging Markets | 9,129 | 7,984 | 14 | 8,845 | 3 | |||||||||||||||
| Pharmaceutical Services and Active Ingredients (PSAI) | 7,540 | 8,553 | (12 | ) | 7,915 | (5 | ) | |||||||||||||
| Proprietary Products & Others | 541 | 547 | (1 | ) | 632 | (14 | ) | |||||||||||||
| Total | 49,194 | 44,175 | 11 | 47,284 | 4 | |||||||||||||||
| 3 |
COVID portfolio
We continue to play our role in the fight against Covid-19 by acting proactively to bring multiple preventive and curative treatment options, including a vaccine. Some of our major Covid-19 products are:
Sputnik V vaccine: We launched the vaccine in India in May 2021 after receiving Emergency Use Authorization (EUA) in April 2021. We are working with RDIF for ramping up supplies. We are also working with six CMOs in India for manufacturing readiness. We have launched it across 80 cities and 2.5+ Lakh people have been vaccinated so far. We are also working on Sputnik Light, for which Russia phase 3 trials will be leveraged for India approval as per recommendation from SEC.
Remdesivir: We launched it in India and ramped up our supplies in this quarter to meet with the higher demand due to surge of the COVID cases during the second wave in India.
Avigan® (Favipiravir): We launched it in India and also in few other markets.
2-deoxy-D-glucose (2-DG): We developed it in collaboration with DRDO lab and received EUA as adjunct therapy for hospitalized moderate to severe Covid-19 patients. We have launched it in India in June 2021.
Molnupiravir: We are collaborating with 5 other pharmaceutical companies for the clinical trial of the investigational oral anti-viral drug for the treatment of mild Covid-19 in an outpatient setting in India.
Other Covid drugs: We are also working on Baricitinib and several other covid drugs for treatment ranging from mild to severe conditions.
Revenue Analysis
Global Generics (GG)
Revenues from GG segment at Rs. 41.1 billion:
| Ø | Year-on-year growth of 17% was driven primarily by branded markets (India and emerging markets) and Europe. The overall growth was on account of new product launches and volume traction in the base business, partly offset by price erosion in some of our products and adverse forex rates. |
| Ø | Sequential growth of 6% driven by higher sales in India. The overall growth was attributable to higher volumes and new product launches, offset partially due to price erosion in certain products. |
North America
Revenues from North America at Rs. 17.4 billion:
| Ø | Year-on-year growth of 1%, driven by launch of new products and increase in volumes of certain of our existing products, which was offset by price erosion in some molecules and adverse forex rates. |
| Ø | Sequential decline of 1%, on account of price erosion in some of our products, partially offset by volume traction and new products launched. |
| Ø | During this quarter, we launched 6 new products. These were Sapropterin Dihydrochloride Powder, Albendazole Tablets, Ertapenem Injection and Icosapent Ethyl Capsules in the US and two products in Canada. |
| 4 |
| Ø | We filed two new ANDAs during the quarter. As of 30th June 2021, cumulatively 93 generic filings are pending for approval with the USFDA (90 ANDAs and 3 NDAs under 505(b)(2) route). Out of these 93 pending filings, 47 are Para IVs and we believe 24 have ‘First to File’ status. |
Europe
Revenues from Europe at Rs. 4.0 billion. Year-on-year growth of 12% and sequential growth of 1% was primarily on account of volume traction in base business and new product launches across our markets, which was partially offset by price erosion.
India
Revenues from India at Rs. 10.6 billion:
| Ø | Year-on-year growth of 69% and sequential growth of 26% was primarily driven by increase in sales volumes of our existing products, led by increase in sale of covid drugs due to the severe second wave witnessed in India. The growth was also aided by contribution from new product launches and increase in sales prices of our existing products. |
| Ø | We launched six new products during the quarter including Sputnik-V vaccine and 2-deoxy-D-glucose for covid. We also launched Curhealth™, a nutritional health mix for building immunity. |
Emerging Markets
Revenues from Emerging Markets at Rs. 9.1 billion. Year-on-year growth of 14% and sequential growth of 3%:
| Ø | Revenues for Russia at Rs. 3.5 billion. Year-on-year growth of 8% was on account of increase in volumes and sales prices in our existing products and new products launches. Sequential decline of 13% was on account of lower volumes, offset partly by increase in sales price of certain products and new products launched. |
| Ø | Revenues from other CIS countries and Romania at Rs. 1.4 billion. Year-on-year growth of 4% driven by new product launches, offset partially by a reduction in sales volumes and prices of certain of our existing products. Sequential decline of 24% was on account of reduction in volumes and price of some of our existing products, offset partly by new products launched. |
| Ø | Revenues from Rest of World (RoW) territories at Rs. 4.2 billion. Year-on-year growth of 25% and sequential growth of 43% was largely attributable to new products launched and volume traction in our base business, partially offset by a reduction in sales prices of some of our products. |
Pharmaceutical Services and Active Ingredients (PSAI)
Revenues from PSAI at Rs. 7.5 billion. Year-on-year decline of 12% and sequential decline of 5%.
| Ø | The decline was on account of a decrease in sales volumes and prices of our existing products, partially offset by new products launched. Year-on-year was also impacted due to customer stocking up in last year. |
| Ø | During the quarter we filed DMFs for two products in the US. |
Proprietary Products (PP) & Others
Revenues from PP & Others at Rs. 541 million. Year-on-year growth of 1% and sequential decline of 14%.
| 5 |
Income Statement Highlights:
| Ø | Gross profit margin for the year at 52.2%: |
| - | Decreased by ~380 bps over previous year and by ~150 bps sequentially, majorly on account of price erosion and increase in inventory provisions related to few products. Q1 FY 21 was higher due to higher export incentives and favourable product mix. |
| - | Gross profit margin for GG and PSAI business segments are at 57.7% and 21.6% respectively. |
| Ø | Selling, general & administrative (SG&A) expenses at Rs. 15.0 billion, increased by 18% on a year-on-year basis and by 5% sequentially. This increase was primarily attributable to investments being done towards marketing of some of our key brands, investments in digitalization and annual increments. The year-on-year increase is also due to additional expenses incurred with the integration of Wockhardt acquired portfolio. |
| Ø | Research & development (R&D) expenses at Rs. 4.5 billion. As % to revenues – Q1 FY22: 9.2% | Q4 FY21: 8.7% | Q1 FY21: 9.0%. We continue our focus on investing in R&D to build a healthy pipeline of new products across our markets including development of biosimilars and products pertaining to COVID-19 treatment. |
| Ø | Other operating income at Rs. 487 million compared to Rs. 118 million in Q1 FY21. The increase was on account of certain settlements and other income during the quarter. |
| Ø | Net Finance income at Rs. 652 million compared to Rs. 605 million in Q1 FY21. |
| Ø | Profit before Tax at Rs. 7.4 billion, declined by 16% year-on-year and increased by 21% sequentially. |
| Ø | Profit after Tax at Rs. 5.7 billion. The effective tax rate is 23.1% for the quarter. |
| Ø | Diluted earnings per share is at Rs. 34.34. |
Other Highlights:
| Ø | EBITDA is at Rs. 10.2 billion and the EBITDA margin is 20.7%. |
| Ø | Capital expenditure is at Rs. 3.2 billion. |
| Ø | Free cash-outflow is at Rs. 6.8 billion. |
| Ø | Net cash surplus for the company is at Rs. 451 million as on June 30, 2021. Consequently, net debt to equity ratio is (0.003). |
| 6 |
Earnings Call Details (05:30 pm IST, 08:00 am EDT, July 27, 2021)
The management of the Company will host an earnings call to discuss the Company’s financial performance and answer any questions from the participants.
Conference Joining Information
Option 1: Express Join with DiamondPass™
Pre-register with the below link and join without waiting for the operator.
https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=2598136&linkSecurityString=94e124d50
| Option 2: Join through below Dial-In Numbers | |
|
Universal Access Number:
|
+91 22 6280 1219 +91 22 7115 8120 |
| International Toll Free Number: |
USA: 1 866 746 2133 UK: 0 808 101 1573 Singapore: 800 101 2045 Hong Kong: 800 964 448 |
No password/pin number is necessary to dial in to any of the above numbers. The operator will provide instructions on asking questions before and during the call.
Play Back: The play back will be available after the earnings call, till August 2nd, 2021. For play back dial in phone No: +91 22 7194 5757 | +91 22 6663 5757, and Playback Code is 51225.
Transcript: Transcript of the Earnings call will be available on the Company’s website: www.drreddys.com
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr Reddy’s operates in markets across the globe. Our Major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com
Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization , including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers’, products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements" sections of our Annual Report on Form 20-F for the year ended March 31, 2021. The company assumes no obligation to update any information contained herein.”
The company assumes no obligation to update any information contained herein.
| 7 |
